ANN ARBOR, Mich., March 3, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (Amex:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today the appointment of George
J. Brewer, M.D., as Senior Vice President of Research &
Development. Dr. Brewer joins the Adeona management team
after serving as the Chairman of the Company’s Scientific Advisory
Board for seven years.
Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus
Professor of Human Genetics and Internal Medicine at the University
of Michigan. He was a member of the National Science
Council’s “Committee on Copper in Drinking Water” convened at the
request of the Environmental Protection Agency in 2000 to consider
the issue of what level of copper in drinking water could be
considered “safe.” Dr. Brewer has published over 500 scientific
papers, several books and is the inventor of oral zinc therapy
approved by the Food & Drug Administration (FDA) in 1997, now
standard of care for chronic Wilson’s disease.
“We are pleased that Dr. Brewer, a respected medical innovator
and developer of zinc-based therapies over his career, accepted our
offer to join Adeona’s management team. As the Chairman of our
Scientific Advisory Board, Dr. Brewer provided significant guidance
with regard to our clinical development programs, and we look
forward to his continued valuable contributions in his new role as
Senior Vice President of Research & Development,” stated James
S. Kuo, M.D., M.B.A., Adeona’s Chairman and CEO. “We also
appreciate the condolences received following the passing of our
colleague and friend, David Newsome. While this was an unexpected
loss for the Company, we believe the appointment of Dr. Brewer
positions our clinical development programs for continued
advancement.”
The study coordinators at the three clinical sites conducting
Adeon
‘/>”/>
SOURCE